House to vote to send 'right to try' bill to Trump’s desk next week

House to vote to send 'right to try' bill to Trump’s desk next week
© Getty

The House will vote next week on Senate-passed legislation aimed at making it easier for sick patients to access experimental drugs — a big priority for President TrumpDonald John TrumpMueller report findings could be a 'good day' for Trump, Dem senator says Trump officials heading to China for trade talks next week Showdown looms over Mueller report MORE, Vice President Pence and groups backed by conservative mega-donors Charles and David Koch.

“This will not only offer a chance for the patient to possibly find treatment but could open possibilities to help others do the same,” House Majority Leader Kevin McCarthyKevin Owen McCarthyHouse leaders need to modernize Congress for the sake of America Overnight Energy: McConnell tees up vote on Green New Deal | Centrist Dems pitch alternative to plan | House Republican likens Green New Deal to genocide | Coca-Cola reveals it uses 3M tons of plastic every year House GOP lawmaker says Green New Deal is like genocide MORE (R-Calif.) said in a statement.

“I am proud we will send this historic legislation to President Trump and offer hope to individuals and families facing dire circumstances.”

In August, the Senate passed Right to Try by unanimous consent. The bill, which Sen. Ron JohnsonRonald (Ron) Harold JohnsonScott Walker considering running for Wisconsin governor or Senate: report GOP moves to rein in president's emergency powers The Hill's 12:30 Report: O'Rourke jumps into 2020 fray MORE (R-Wis.) championed, lets sick patients request access to treatments the Food and Drug Administration (FDA) hasn’t yet approved.

House Energy and Commerce Committee Chairman Greg WaldenGregory (Greg) Paul WaldenThe 25 Republicans who defied Trump on emergency declaration House GOP lawmaker says Green New Deal is like genocide Overnight Health Care — Presented by PCMA — FDA issues proposal to limit sales of flavored e-cigs | Trump health chief gets grilling | Divisions emerge over House drug pricing bills | Dems launch investigation into short-term health plans MORE (R-Ore.) had expressed concerns with the Senate bill, however. He worked to hammer out a different version that, among other changes, further defined the criteria necessary for a patient to be able to receive experimental drugs.

But on Thursday, Walden appeared to offer support for the Senate-passed bill, and laid blame on Senate Democrats.

“It is time for the House to do what Senate Democrats won’t and send a right-to-try bill to the President’s desk, bringing hope to terminally-ill patients across the country,” Walden said in a statement. “I applaud President Trump and Vice President Pence for their tireless support for right-to-try legislation and the patients whose lives hang in the balance.”

In late March, the House bill passed its version of Right to Try in a 267-149 vote, largely along party lines.

The announcement on Thursday that it will take up the Senate's bill comes as congressional momentum had appeared to grind to a halt the past two months, leaving the path forward on the measure unclear.

Senate Democrats last year didn’t object to the bill Johnson introduced with Sen. Joe DonnellyJoseph (Joe) Simon DonnellyLobbying World Lobbying World Overnight Energy: Trump taps ex-oil lobbyist Bernhardt to lead Interior | Bernhardt slams Obama officials for agency's ethics issues | Head of major green group steps down MORE (D-Ind.), which also sidesteps the FDA.

But since the opposition from House Democrats, Senate Minority Leader Charles SchumerCharles (Chuck) Ellis Schumer4 in 5 Americans say they support net neutrality: poll GOP senator: Trump's criticism of McCain 'deplorable' Schumer to introduce bill naming Senate office building after McCain amid Trump uproar MORE (D-N.Y.) has voiced concerns about taking the FDA out of the equation and objected to a request to bring the House bill up by unanimous consent.

House Democrats voiced concerns about patient safety that were echoed by some advocacy groups.

“By allowing patients access to investigational treatments that have only completed a phase one clinical trial, patients will be exposed to treatments with no or relatively little data that they are actually effective,” the top Democrat on the House Energy and Commerce Committee, Rep. Frank Pallone Jr.Frank Joseph PalloneBooker takes early lead in 2020 endorsements Hillicon Valley: EU hits Google with .7 billion antitrust fine | GOP steps up attack over tech bias claims | Dems ask FTC for budget wishlist | Justices punt on Google privacy settlement Dems ask FTC if it needs more money to protect privacy MORE (N.J.), said during the debate on the House floor in March.

Opponents of the bill had also pointed to FDA’s compassionate use program, saying the agency approves 99 percent of requests to let a patient use an experimental drug. They also said the bill provides a sense of “false hope,” since drug manufacturers aren’t required to provide the drug to patients who ask.

Supporters of the measure have argued it's safe and that people with a terminal illness should have all tools at their disposal to try a drug that could possibly help them.

“For years, terminally ill patients and their families have been fighting for the right to hope and the freedom to try to save their own lives," Johnson said. "I truly appreciate today’s announcement that House leadership plans to advance this effort by taking up my bill that passed the Senate unanimously."

--Updated at 12:49 p.m.